Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database

被引:4
作者
Wu, Jinbo [1 ]
Liu, Hongjun [1 ]
Hu, Taobo [1 ]
Wang, Shu [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Breast Surg, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Gene expression; TCGA; MENOPAUSAL HORMONE-THERAPY; TUMOR MICROENVIRONMENT; DOUBLE-BLIND; RISK; TAMOXIFEN; EPIDEMIOLOGY; CHEMOTHERAPY; TRASTUZUMAB; PROGRESSION; ANTIBIOTICS;
D O I
10.1186/s41065-022-00230-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Breast cancer has remained the most common malignancy in women over the past two decades. As lifestyle and living environments have changed, alterations to the disease spectrum have inevitably occurred in this time. As molecular profiling has become a routine diagnostic and objective indicator of breast cancer etiology, we analyzed changes in gene expression in breast cancer populations over two decades using The Cancer Genome Atlas database. Methods We performed Heatmap and Venn diagram analyses to identify constantly up- and down-regulated genes in breast cancer patients of this cohort. We used Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to visualize associated functional pathways. Results We determined that three oncogenes, PD-L2, ETV5, and MTOR and 113 long intergenic non-coding RNAs (lincRNAs) were constantly up-regulated, whereas two oncogenes, BCR and GTF2I, one tumor suppression gene MEN1, and 30 lincRNAs were constantly down-regulated. Up-regulated genes were enriched in "focal adhesion" and "PI3K-Akt signaling" pathways, etc., and down-regulated genes were significantly enriched in "metabolic pathways" and "viral myocarditis". Eight up-regulated genes exhibited doubled or higher expression and the expression of three down-regulated genes was halved or lowered and correlated with long-term survival. Conclusions In this study, we found that gene expression and molecular pathway enrichments are constantly changing with time, importantly, some altered genes were associated with prognostics and are potential therapeutic targets, suggesting that the current molecular subtyping system must be updated to keep pace with this dynamic change.
引用
收藏
页数:11
相关论文
共 90 条
  • [1] Global trends in breast cancer incidence and mortality 1973-1997
    Althuis, MD
    Dozier, JM
    Anderson, WF
    Devesa, SS
    Brinton, LA
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (02) : 405 - 412
  • [2] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Alva, Ajjai S.
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Hansra, Damien
    Calfa, Carmen J.
    Khalil, Maged F.
    Ahn, Eugene R.
    Cannon, Timothy L.
    Crilley, Pamela
    Fisher, Julie G.
    Haslem, Derrick S.
    Shrestha, Sagun
    Antonelli, Kaitlyn R.
    Butler, Nicole L.
    Warren, Sasha L.
    Rygiel, Andrew L.
    Ranasinghe, Shamika
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2443 - +
  • [3] A screen for deubiquitinating enzymes involved in the G2/M checkpoint identifies USP50 as a regulator of HSP90-dependent Wee1 stability
    Aressy, Bernadette
    Jullien, Denis
    Cazales, Martine
    Marcellin, Marlene
    Bugler, Beatrix
    Burlet-Schiltz, Odile
    Ducommun, Bernard
    [J]. CELL CYCLE, 2010, 9 (18) : 3815 - 3822
  • [4] Treatment of HER2-positive breast cancer: current status and future perspectives
    Arteaga, Carlos L.
    Sliwkowski, Mark X.
    Osborne, C. Kent
    Perez, Edith A.
    Puglisi, Fabio
    Gianni, Luca
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) : 16 - 32
  • [5] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
    Bachelot, Thomas
    Bourgier, Celine
    Cropet, Claire
    Ray-Coquard, Isabelle
    Ferrero, Jean-Marc
    Freyer, Gilles
    Abadie-Lacourtoisie, Sophie
    Eymard, Jean-Christophe
    Debled, Marc
    Spaeth, Dominique
    Legouffe, Eric
    Allouache, Djelila
    El Kouri, Claude
    Pujade-Lauraine, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) : 2718 - 2724
  • [6] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    [J]. LANCET ONCOLOGY, 2017, 18 (07) : 904 - 916
  • [7] Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
    Basso, AD
    Solit, DB
    Munster, PN
    Rosen, N
    [J]. ONCOGENE, 2002, 21 (08) : 1159 - 1166
  • [8] Long Noncoding RNA and Cancer: A New Paradigm
    Bhan, Arunoday
    Soleimani, Milad
    Mandal, Subhrangsu S.
    [J]. CANCER RESEARCH, 2017, 77 (15) : 3965 - 3981
  • [9] RETRACTED: LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis (Retracted Article)
    Bi, Huifeng
    Shang, Zhenhua
    Jia, Chunsong
    Wu, Jiangtao
    Cui, Bo
    Wang, Qi
    Ou, Tongwen
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 11277 - 11288
  • [10] Bu Xiaoyun, 2019, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V44, P741, DOI 10.11817/j.issn.1672-7347.2019.190142